The spec pharma said two phase 3 trials testing apaziquone's use in bladder cancer after surgery failed to show a statistically significant improvement in tumor recurrence after two years. There must have been a trend in the right direction, however, because when the data from the two trials were pooled, the endpoint reached statistical significance. It's the same concept as how getting seven out of 10 heads isn't that weird, but getting 70 out of 100 might make you think the coin was rigged.
Spectrum and partner Allergan
The data should give the companies confidence that running larger phase 3 trials would should show a statistically significant improvement, but the endpoint requires following patients for two years, so we're years away from an approval if they went that route.
While apaziquone doesn't look as if it'll be contributing to the bottom line anytime in the near future, Allos Therapeutics'
Allos' fit with Spectrum is perfect, and it's certainly better than AMAG Pharmaceuticals
And the synergies should keep coming, since Folotyn is headed for approval in the EU. Spectrum's move to acquire the rights to Zevalin outside the U.S. doesn't look nearly as risky.
Was Spectrum's haircut today justified? Probably. Apaziquone would have tackled an indication that hasn't seen a new drug approved for it in more than 20 years. Even as good as the fit with Allos looks, sales of Folotyn totaled only $50 million last year; it's not going to be a major money maker for the company.
Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
3 Biotech Stocks to Be Thankful for This Year
If you notice a relative who can't stop grinning at the Thanksgiving dinner table, they're probably holding shares of these biotech stocks.
Why Spectrum Pharmaceuticals Stock Soared in October
Spectrum's preliminary lung cancer data sparked a noteworthy rally in its shares last month.
3 Healthcare Stocks That Soared This Week: Are They Buys?
Can the sizzling momentum continue for TransEnterix, uniQure, and Spectrum Pharmaceuticals?